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Abstract
Many human cancers are associated with characteristic chromosomal rearrangements, especially
hematopoietic cancers such as leukemias and lymphomas. The first and most critical step in the
rearrangement process is the induction of two DNA double-strand breaks (DSB). In all cases, at
least one of the two DSBs is generated by a pathologic process, such as (1) randomly-positioned
breaks due to ionizing radiation, free radical oxidative damage, or spontaneous hydrolysis;
(2) breaks associated with topoisomerase inhibitor treatment; or (3) breaks at direct or inverted
repeat sequences, mediated by unidentified strand breakage mechanisms. In lymphoid cells, one of
the two requisite DSBs is often physiologic, the result of V(D)J recombination or class switch
recombination (CSR) at the lymphoid antigen receptor loci. The RAG complex, which causes the
DSBs in V(D)J recombination, can cause (4) sequence-specific, pathologic DSBs at sites that fit the
consensus of their normal V(D)J recombination signal targets; or (5) structure-specific, pathologic
DSBs at regions of single- to double-strand transition. CSR occurs specifically in the B-cell lineage,
and requires (6) activation-induced cytidine deaminase (AID) action at sites of single-stranded
DNA, which may occur pathologically outside of the normal target loci of class switch
recombination regions and somatic hypermutation (SHM) zones. Recent work proposes a seventh
mechanism: the sequential action of AID and the RAG complex at CpG sites provides a coherent
model for the pathologic DSBs at some of the most common sites of translocation in human
lymphoma – the bcl-2 gene in follicular lymphoma and diffuse large B-cell lymphoma, and the bcl-1
gene in mantle cell lymphoma.
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Somatic cell chromosomal rearrangements are either
physiologic events [V(D)J recombination or class switch
recombination (CSR)] exclusive to lymphoid cells, or
they are pathologic events, often found in neoplasia.
This review focuses primarily on these somatic cell types.
Constitutional rearrangements which arise during game-
togenesis and the first nuclear divisions of the fertilzed
egg, and rearrangements which occur during evolution
and population selection are beyond the scope of this
review, but similar principles of breakage and rejoining
apply, particularly the rejoining of double-strand breaks
by nonhomologous DNA end joining (NHEJ).
All cancers begin with somatic cell mutations. Chromo-
somal rearrangements are important types of mutations
initiated by two double-strand DNA breaks (DSBs),
resulting in four DNA ends (Figure 1). The four DNA
ends can be rejoined in a new configuration as a
translocation. Translocations are found at high frequen-
cies in many malignancies, especially in the hemato-
poietic system, but are insufficient to drive
carcinogenesis. Thus, they appear to be critical initiating
events in such cancers, after which a variety of secondary
and apparently less consistent mutations are required to
complete the process.
Translocations occur in two steps: a cutting step and a
joining step. The joining step is usually done by the major
repair pathway for double-strand DNA breaks, NHEJ.
NHEJ joins the ends of most DSBs in most eukaryotic
cells, and it can join any two incompatible or compatible
DNA ends, even though they usually have no homology.
(In rare patients with mutations in NHEJ or in mouse
models lacking all NHEJ factors, other enzymes can
substitute for the missing factors, and this is often called
alternative NHEJ [1-4].) The other major pathway is
called homologous recombination, which is largely
restricted to late S and G2 of the cell cycle and requires
hundreds of base pairs of homology. The natural causes of
DSB formation – the cutting mechanisms – are often
more difficult to determine and are the focus of this
review. As with somatic cell rearrangements, one can
organize DSBs into those that are pathologic (maladap-
tive) and those that are physiologic (programmed or
adaptive). Physiologic DSBs participate in physiologic
rearrangements whereas pathologic DSBs by definition,
do not. In the majority of pathologic chromosomal
rearrangements, one of the two requisite DSBs is
pathologic, and the other is physiologic (occurs during
the course of a physiologic gene rearrangement process).
Physiologic causes of double-strand DNA breaks
In the somatic cells of multicellular eukaryotes, physio-
logic DSBs only occur in the lymphoid cells of the
vertebrate immune system as a way of generating a
diverse array of receptors for binding to antigens of
invading organisms.
V(D)J recombination
B-cells and T-cells bind and recognize foreign antigens
using the variable domains of B-cell receptors (immu-
noglobulins, or Ig) and T-cell receptors (TCR), respec-
tively. Igs and TCRs are encoded by the Ig and TCR gene
loci, which are organized into a set of V gene segments,
followed sometimes by a set of D gene segments,
followed by a set of J gene segments. Using the process
of V(D)J recombination, early B cells (pro-B and pre-B
cells residing in the bone marrow) and early T cells (pro-
T and pro-T residing in the thymus) select one V, one D,
and one J segment and join them together into the
antigen receptor variable domain exon, deleting the
intervening segments [5-9].
These early lymphoid cells express the RAG1 and RAG2
proteins, which combine with the constitutively-
expressed HMGB1 or 2 to form the RAG complex. The
RAG complex binds at special sequences termed recom-
bination signal sequences (RSS) located directly adjacent
to the V, D, or J segments. RSS are composed of a
heptamer of consensus CACAGTG, and a nonamer of
consensus ACAAAAACC, with an intervening spacer of
12 or 23 bp. A 12 bp-spaced RSS is termed a 12-RSS and
a 23 bp-spaced RSS is termed a 23-RSS. After binding, the
RAG complex makes a nick 5’ of the RSS heptamer
sequence. This results in a single-strand break with a 5’
phosphate and a 3’ hydroxyl (OH). One 12-RSS and one
23-RSS must synapse, or bind the same RAG complex,
before the complex can progress to the next step, which
is use of the 3’ OH to attack the opposite DNA strand,
creating a hairpin DNA end at the terminus of the V, D or
J segment, and a blunt DNA end containing the RSS.
Once the hairpins are generated, enzymes of the NHEJ
pathway open the hairpins and join the resulting ends
[10,11]. As a result, the requisite antigen receptor gene
segments are assembled next to one another, forming a
functional antigen receptor variable domain exon.
In B and T cell development, V(D)J recombination
occurs not only in the earliest lymphoid precursors, but
also in later stages of B and T cell development in
secondary V(D)J recombination events called receptor
editing or receptor revision. (Recombination failures that
lead to translocations can occur at any point [1-4].)
Class switch recombination
After V(D)J recombination, B cells, but not T-cells, can
later undergo a second type of recombination event
BMC Genomics 2010, 11(suppl 1):S1 http://www.biomedcentral.com/1471-2164/11/S1/S1
Page 2 of 9
(page number not for citation purposes)
called class switch recombination (CSR), which changes
the type of immunoglobulin they produce from IgM and
IgD to IgG, IgA, or IgE. This change in the constant
portion of the Ig heavy chain enhances phagocytosis of
antibody-bound antigens and allows antibodies to
penetrate extravascular regions of the body, such as
epithelial surfaces in the lungs, gastrointestinal tract, and
genitourinary system.
Downstream of the Ig heavy chain J segments is a set of
constant domains, each preceded by a several kilobases-
long CSR target region termed a class switch sequence
[12,13]. Following successful V(D)J recombination, Ig
heavy chain transcription runs through the variable domain,
the IgM switch sequence, and the IgM and IgD constant
regions. Alternative splicing determines production of IgM
or IgD. Subsequently, B-cells can be activated by cytokine
stimulation, which drives transcription through the IgG,
IgA, or IgE switch regions. Different cytokines drive
transcription through different switch regions. The RNA
generated at switch regions is very G-rich, having a tendency
to thread-back onto the template DNA strand from which
they were transcribed, and causing formation of what is
called an R-loop structure [14,15]. In an R-loop, the RNA is
hybridized to its template DNA strand, with the nontem-
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Features of some neoplastic chromosomal translocations. Chromosomal translocations in somatic cells are most
often encountered in the context of neoplasia. Constitutional translocations arise during gametogenesis or early divisions of
the fertilized egg. It is useful to dissect the chromosomal translocation process into two phases: the causes of the breaks and
then the rejoining of the four broken ends. [Most chromosomal translocations involve two DSBs, though some can occur
during DNA replication (see text).] In neoplastic translocations, the causes of the two DSBs can be different. In this example,
one chromosome break is of the CpG-type (see text), and the other can be a V(D)J-type or a random DSB. In addition, breaks
can be of the class switch type (CSR-type) or somatic hypermutation type (SHM-type). The V(D)J-type, CSR-type, SHM-type,
and CpG-type are limited to lymphoid cells, and further limited by stage of differentiation (see text). Random breaks are
thought to be due to oxidative free radicals (reactive oxygen species), ionizing radiation (IR), or topoisomerase failures. The
joining of the four DNA ends is done by nonhomologous DNA end joining (NHEJ) in most cases. The causes of the breaks all
generate heterogeniety at the break site, and NHEJ creates additional heterogeneity at the joining site. Hence, even when both
translocation junctions are sequenced, one can only trace the site or boundary of the original breaks to a zone of at least
several nucleotides (often longer, such as 10-20 bp). Less commonly, no nucleotides are lost from either DSB site, and this
permits determination of the specific phosphodiester bonds at which the original DSBs occurred. This proved useful for
defining the CpG-type break (see text). Some of the specific translocations discussed here have been previously diagrammed in
more detail [26-28]. The normal V(D)J and class switch recombination processes have been previously diagrammed [5-9].
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CSR requires a protein called activation-induced deami-
nase (AID) [16], predominantly expressed in B cells
located in the germinal centers of the lymph nodes,
spleen, and Peyer's patches. AID is a cytidine deaminase
that converts cytosine (C) to uracil (U) or 5-methylcy-
tosine (5-meC) to thymine (T). Importantly, AID only
functions on single-stranded DNA (ssDNA) and is
therefore a structure-specific deaminase [17-19]. AID
generates Us in the nontemplate strand ssDNA at switch
regions, which are excised by uracil DNA glycosylase
(UDG), leaving abasic sites [20]. Apurinic/apyrimidinic
endonuclease (APE) nicks the phosphodiester bond on
the 5’ side of any abasic site. Single-stranded regions
occur on the template strand at the edges of the R-loop,
where the RNA ceases to hybridize. Nicking on the
nontemplate strand and on the template strand thus
results in a DSB. We call these types of DSBs CSR-type.
This term is useful for some translocations that require
AID, but where the break is at a genomic site other than
the Ig class switch regions. Such locations could be called
off-target, and an example is the c-myc translocation in
Burkitt lymphoma [3,4].
AID also functions in somatic hypermutation (SHM) at
Ig variable domains of the light and heavy chains,
causing point mutations, some of which increase the
affinity of the Ig for its antigen [20]. It is not yet clear
how single-strandedness arises at the variable domains
to permit AID to function in SHM. Transcription alone
appears to be insufficient, as not all transcribed
sequences undergo SHM.
Pathologic causes of double-strand DNA breaks
Pathologic DSBs are arbitrarily defined as DSBs which
serve no physiologic purpose and may lead to cell
dysfunction.
Random DNA breaks due to ionizing radiation or
oxidative free radicals
In many chromosomal rearrangements, the DSBs at one
or both genes appear to be located randomly within
large regions of many kilobases. Random positioning
and the apparent lack of sequence propensity are
suggestive of sequence-nonspecific DSB mechanisms
such as oxidative free radicals, ionizing radiation, or
less commonly, spontaneous DNA backbone hydrolysis.
About half of the natural ionizing radiation of the
environment originates from natural heavy metals of the
earth, such as uranium, thorium, and even potassium.
The other half of the ionizing radiation emanates from
cosmic radiation that is not entirely blocked by the
atmosphere. In total, about 3 x 108 ionizing radiation
particles pass through each of us every hour [10],
producing hydroxyl free radicals from water in their
wake. This tract of hydroxyl free radicals causes cluster
damage on DNA, thereby breaking both DNA strands.
About 0.1% of the oxygen that we breathe is converted to
free radicals [21]. This generates 3 x1022 free radicals per
hour within each of us, and these damaging free radicals
are distributed across the 1014 cells of the human body.
Free radicals cause predominantly single-strand DNA
damage, but two nearby such events can result in a DSB.
RAG action at cryptic RSS sites at off-target locations in a
sequence-specific manner: V(D)J-type breaks
The RSS heptamer/nonamer consensus sequence is by no
means unique to the Ig and TCR loci, and the RAG
complex can cut at sites which differ substantially from
the 16 bp consensus [22]. The minimal motif for RAG
nicking is only CAC. Thus the RAG complex can act at
RSS-like non-antigen receptor locus sites, termed cryptic
RSS (cRSS). This occurs in many of the rearrangements
observed in human T-cell acute lymphoblastic lym-
phoma [23-25]. In these cases, instead of the RAG
complex pairing a 12-RSS with a 23-RSS, a 12-RSS pairs
with a 23-cRSS or a 23-RSS pairs with a 12-cRSS. We call
these breaks V(D)J-type breaks because they are occur-
ring via the same mechanism as normal V(D)J recombi-
nation, regardless of the fact that one of the sites is
outside of the usual antigen receptor loci (that is, it is
off-target).
RAG action at DNA bubble structures and other regions of
heterology in a structure-specific manner
In addition to its sequence-specific mode of cutting, the
RAG complex can also nick in a structure-specific
manner at sites of transition from dsDNA to ssDNA,
such as occurs at the edges of bubble DNA structures or
even single-base mismatches [26-28]. Such activity by
the RAG complex may have arisen because the RAG
complex is accustomed to creating hairpin structures,
which involves substantial DNA distortion. Hence, any
region of mismatch or slippage is a potential target for
nicking by the RAG complex in lymphoid cells.
RAG-mediated transposition as a mechanism for
chromosomal rearrangement
From 1998 to 2007, several laboratories proposed that
the RAG complex might insert the blunt RSS-containing
ends from V(D)J recombination, termed signal ends,
into new locations in the genome. This is called RAG
transposition, and occurs at a low level using a truncated
form of the RAG proteins called core RAGs (reviewed in
[7]). However, efforts to find RAG transposition events
in vivo showed that these were much less common than
random integration of DNA [29]. Finally, there are no
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examples of human lymphoid malignancies (or any
other type of malignancy) where the genome was altered
by a RAG transpositional insertion of signal ends (or any
other apparent variant of such a transposition).
AID action at off-target locations
As mentioned in the above discussion of class switch
recombination, AID can convert C to U or methyl C or T
at any region of ssDNA. This appears to occur not only at
the switch sequences and variable domains of the Ig loci,
but also at some pathologic locations, such as some
oncogenes like c-myc [3,4]. When targeted by AID, these
regions may sustain point mutations or DSBs [30]. AID
action at the IgH switch region during CSR and
independent AID action at the c-myc gene to create a
DSB are thought to be the basis of the two initiating
DSBs in both mouse and human c-myc translocations
[1-4]. One could regard breaks of this type as CSR-type
breaks (as mentioned above in the discussion of class
switch recombination) or SHM-type breaks, where SHM
refers to AID initiated events of the type similar to what
normally occurs in somatic hypermutation.
Putative combined action of AID and RAGs at CpG sites:
CpG-type breaks
Recently, we reported that DSBs at certain loci in pro-B/
pre-B stage translocations – the bcl-2 from t(14;18), the
bcl-1 from t(11;14), and E2A from t(1;19) – have a strong
propensity to occur at the dinucleotide sequence CpG.
The bcl-2 translocation is the most common translocation
in cancer, occurring in >90% of follicular lymphomas and a
third of diffuse large cell lymphomas. Fifty percent of the
breaks at the bcl-2 gene occur within the major breakpoint
region (MBR), which is a 175 bp hotspot in the 3’most exon
in the region encoding the 3'UTR. Two less-frequently used
hotspots are located 18 and 29 kb further distal to the bcl-2
gene, the 105 bp bcl-2 intermediate cluster region (icr), and
the 561 bp bcl-2 minor cluster region (mcr), respectively.
Any of the CpG sites within any of these three bcl-2
translocation zones can be a target for a DSB [28]. Thirteen
percent of bcl-2 translocation breaks are located in the icr,
and 5% in the mcr.
The use of CpGs applies also to the bcl-1 major
translocation cluster, which is the location involved in
the t(11;14) translocation. The bcl-1 translocation occurs
in almost all mantle cell lymphomas, with 30% of the
breaks occurring at the 150 bp bcl-1 major translocation
cluster (MTC).
CpG-type breaks also occur in a third lymphoid
malignancy, the t(1;19) in a small percentage of pre-B
ALLs, a translocation which occurs between the Pbx1
gene and the E2A gene. The breaks at the E2A gene occur
in a zone of only 23 bp, and these DSBs are also
significantly clustered around CpG sites [28]. All three
translocations involving the bcl-2, bcl-1 and E2A occur at
the pro-B/pre-B stage of B-cell development.
The bcl-2 MBR is reactive with a chemical probe for
single-strandedness called bisulfite [27]. Like the bcl-2
MBR, this bcl-1 MTC is relatively small (150 bp) and
features a similar reactivity to bisulfite [31]. These highly
bisulfite reactive zones are rich in runs of Cs. Based on
circular dichroism, X-ray crystallography, NMR, and
chemical probing, such runs of Cs tend to adopt a
DNA structure that is intermediate between B-form DNA
and A-form DNA, termed B/A-intermediate [31]. The B/
A-intermediate structure has more rapid opening
kinetics, perhaps accounting for part of the observed
increase in bisulfite reactivity. Such unusual DNA
regions may be more prone to slippage events, perhaps
induced by DNA replication or transcription. This may
then account for their vulnerability in minichromosomal
recombination assays [27].
The Cs of the CpGs within or directly adjacent to these B/
A-intermediate zones are at increased risk of undergoing
deamination [28]. This deamination does not apply to
all Cs in the region, but only the Cs that are within CpG
sites. The only distinctive feature about such Cs within
CpGs is that they can be methylated by DNA methyl-
transferase. When regular Cs deaminate, they become U,
resulting in a U:G mismatch. But when methyl Cs
deaminate, they become T, resulting in a T:G mismatch.
The repair of U:G mismatches is very efficient, but the
repair of T:G mismatches is not efficient. In fact, T:G
mismatch repair is so inefficient, it accounts for about
half of the point mutations at the p53 gene across a wide
range of human cancers. These T:G mismatch sites are
always at CpG sites.
What causes the break at these T:G mismatch sites?
Interestingly, this deamination at these lymphoid trans-
location hotspots appears to occur at the pre-B stage of
differentiation. This is the stage of B cell development
when D to J recombination is occurring most vigorously.
Since the bcl-2 and bcl-1 translocations occur at this
stage, this seems likely to be the stage of the transloca-
tion. We have shown that the RAG complex can cause a
DSB at sites of small bubble structures, and even single
base pair mismatches. (As mentioned above, this action
by the RAG complex reflects its structure-specific
nuclease activity, perhaps a feature that reflects the
structure-specific actions by the RAG complex during the
hairpin formation step of V(D)J recombination.) There-
fore, we have proposed that the RAG complex makes the
DSBs at the sites of T:G mismatch [28].
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If the RAG complex causes the DSBs at CpG sites, then
why do such CpG-type breaks not occur in pre-T cells,
which also express the RAG enzyme complex? The B cell
lineage expresses a cytidine deaminase for class switch
recombination and somatic hypermutation. As men-
tioned above, this enzyme is called activation-induced
deaminase (AID). AID is expressed in B cells but not
other somatic cells. AID is most highly expressed in B
cells when they are in the germinal centers. However, a
low level of AID expression has been described in pre-B
cells [32-34]. Moreover, B cells just leaving the bone
marrow, called transitional B cells, also are thought to
express AID [1]. Therefore, there is a period of time when
B cells are completing V(D)J recombination and begin-
ning to express AID when both AID and the RAG
complex are present in the B cells. AID has been shown
to be capable of deaminating methyl C to T. Therefore,
we propose that AID is likely responsible for the
mutation of meC to T at CpG sites in early B cells. The
resulting T:G mismatch is then cut by the RAG complex,
resulting in a DSB. This model explains three peaks of
translocation located within the bcl-2 MBR, all of which
are centered at CpG sites [28].
Other causes of pathologic DSBs of unknown mechanism
Certain translocations are heavily associated with type II
topoisiomerase inhibitor therapy [35]. After such ther-
apy, some patients develop secondary malignancies with
these characteristic translocations. Topoisomerases in
general make single- or double-strand breaks in order to
wind or unwind DNA, thus they have a nuclease activity
as part of their function. After winding or unwinding the
DNA, they normally reseal the break(s). It has been
proposed that interruption or prevention of resealing
may result in stable breaks seen in chromosomal
rearrangements [36,37].
Some DSBs arise at sites nearby direct or inverted DNA
repeats. Such repeats may give rise to slipped DNA
structures containing regions of single-stranded DNA,
which may be targets for cleavage. The best example of
this is the constitutional translocation t(11;22)(q23;
q11), which contains an AT-rich palindrome of several
hundred bases, with potential for cruciform formation.
Combination of multiple DSB mechanisms within a
rearrangement
Given that two DSBs are required to generate a
translocation, the two breaks are often not related to
one another. In the bcl-2 and bcl-1 translocations, for
example, the break at the IgH locus is a V(D)J-type break
generated by the sequence-specific action of the RAG
complex during V(D)J recombination. (One could
consider this to be a failure in the completion of the
normal V(D)J recombination process [23-25].) The DSB
at the bcl-2 or bcl-1 locus is a CpG-type break that has
been proposed to be due to the sequential action of AID
and the structure-specific nicking activity of the RAG
complex [28].
Even within a given locus, there can be a wide range of
DSB mechanisms. The SCL and LMO2 loci predomi-
nantly both sustain V(D)J-type DSBs, but one-third or
more of the DSBs are incompatible with the sequence
requirements for V(D)J-type DSBs, and these may be due
to free radical damage, ionizing radiation, or topoi-
somerase failures. Different loci within a single cell are
therefore prone to different types of DSB mechanisms.
Replication-induced DSBs
During DNA replication, deletions can arise due to
slippage of the synthesizing strand on the template
strand. Chromosomal rearrangements that occur at
specific hotspots, whether in cancer in somatic cells or
during gametogenesis/initial developmental divisions as
constitutional translocations, are called recurrent trans-
locations that can be seen across many patients. Non-
recurrent translocations are those that occur at different
locations from one patient to another but alter or
inactivate a gene that causes a disease. Unlike the
recurrent translocations that we have discussed in cancer
above, the mechanisms that cause the strand exchange in
nonrecurrent translocations appear to involve template
switching during replicative DNA synthesis. These tem-
plate switches can occur at small regions of DNA sequence
homology, such as 5 bp. This template switching has been
called microhomology-mediated breakage-induced repli-
cation (MMBIR) or Fork Stalling and Template Switching
(FoSTeS). For nonrecurrent translocation junctions that
involve several long stretches of sequence from regions of
the genome that are normally separated from one
another, multiple template switching events has been
proposed as a mechanism [38,39].
Biological factors and neoplastic chromosomal
translocations
This review has not emphasized the neoplastic cellular
proliferation advantage provided by these chromosomal
rearrangements [40,41]. Rather, here we have focused on
the factors that make some very focal (23 to 561 bp)
DNA sequences particularly prone to repeated rearrange-
ment events in a wide range of different patients, even
though the translocations could have arisen within zones
of 29 kb, as in the case of the bcl-2 gene or 100 kb, as in
the bcl-1 translocation.
Recurrent rearrangements found in particular cancers are
oncogenic, and by nature provide a growth advantage.
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Some such rearrangements result in the genesis of
chimeric fusion transcripts between two genes, and
such is the case for the t(1;19) translocation involving
E2A and Pbx1 [42-47]. In these cases, the DSB could, in
principle, occur across much of the length of a given
intron within each gene so as to create the neoplastic
fusion transcript. For the Pbx1 gene, the breaks occur
diffusely in an intron in this way, and these DSBs are
likely random and due to mechanisms such as free
radical damage (i.e., ROS), ionizing radiation (IR), or
topoisomerase failures. But the break at the E2A gene is
focused to a 23 bp zone that is 150-fold tighter than the
3.2 kb intron in which it is located, and this is a CpG-
type break site.
The same concepts apply to the t(9;22) translocation, the
hallmark in chronic myeloid leukemia (CML) and also
common in the t(9;22) ALLs in which the BCR gene and
the ABL gene fuse and produce a p210 fusion transcript
[48]. DSB formation at both the BCR gene and the ABL
gene occur over broad translocation zones of more than
5.8 kb at the BCR gene and a much broader approxi-
mately 200 kb zone at the ABL gene [49-52]. Among the
translocations that give rise to malignancy, the fusion
gene minimally contains the first exon of BCR, which
contains an oligomerization domain, and almost always
contains exons 2 to 11 of ABL, which encode the tyrosine
kinase. The 200 kb breakage zone at ABL contains
translocation break sites distributed anywhere between
alternative exons 1a and 1b. The 5.8 kb breakage zone at
BCR is the major breakpoint cluster region (M-BCR) and
encompasses a region containing exons 13 and 14. [A
minor BCR, m-BCR (~130 kb in length), can give rise to
a shorter p190 fusion gene and is located in intron 1.]
Leukemia only arises from those fusion genes that can
produce an mRNA encoding a functional protein: thus,
only certain splice combinations produce a BCR/ABL
protein. Therefore, it is not the increased breakage in the
BCR that makes it a translocation zone; it is the lack of
growth advantage outside of the zone which demarcates
the boundaries of where the zone can be.
Again, the DSBs at both the BCR and ABL are likely due
to random causes (ROS, IR, toposimerase failures).
Therefore, it is useful to distinguish between focal
hotspots (i.e., high concentrations of breaks at small
zones within the total breakage zone, usually <200 bp),
as in the bcl-2, bcl-1 or E2A cases, and broad transloca-
tion zones that often span the length of an entire intron
(usually kilobases, and sometimes tens of kilobases or
more).
For translocations involving focal hotspots, there are two
factors that make the translocation clinically apparent:
the increased propensity for DSB and the growth
advantage. In contrast, for translocations that have no
hotspot propensity, then only the growth advantage acts
to bring the translocation to the level of clinically
attention [28].
Relevance to constitutional chromosomal
rearrangements and to changes in a genome
during evolution
We have focused here on neoplastic chromosomal
rearrangements. As mentioned, the breakage and rejoin-
ing mechanisms and concepts may be relevant to
constitutional translocations or changes in a genome
during evolution. The most common constitutional
chromosomal rearrangement is the t(11;22) in the
Emanuel Syndrome [53]. In this case, inverted repeats
result in cruciform formation, creating a DNA structure
that is vulnerable to DNA enzymes that can act on
various portions of the cruciform structure. Once broken,
the DNA ends likely join by NHEJ. Hence, the concepts
of DNA structural deviation, followed by inadvertent
action of a physiologic DNA enzyme to cause the break
and rejoining by NHEJ have more general relevance.
During evolution, some of the chromosomal rearrange-
ments that arise during speciation are almost certain to
share themes with those discussed here, including
breakage at sites of DNA structural variation and joining
by NHEJ. Replication-based mechanisms mentioned
briefly here and discussed in detail elsewhere are also
likely to be very important for major genomic rearrange-
ments [38,39].
List of abbreviations used
NHEJ: nonhomologous DNA end joining; RAG: recom-
bination activating gene; AID: activation-induced dea-
minase; RAG complex: RAG1:RAG2:HMGB1 proteins in
a complex; V(D)J: variable (diversity) joining, which
refers to segments of DNA joined by the RAG1:RAG2:
HMGGB1 complex to generate the variable domain
exons of immunoglobulins and T-cell receptors; V(D)J
recombination: the process of joining of V, D, and J
coding segments together to form the variable domain
exon; RSS: recombination signal sequence, which is also
called the signal sequence. The RSS or signal sequence is
the site where the RAG complex binds. The RSS or signal
sequence consists of a heptamer (CACAGTG; this
consensus sequence can vary at the right side from one
signal to another) and a nonamer (ACAAAAACC; this
consensus sequence varies quite a bit); Coding sequence:
any sequence adjacent to an RSS; Coding end: the DNA
end generated by RAG cleavage. This has a hairpin
configuration until it the hairpin is opened by the
Artemis:DNA-PKcs complex; Signal end: the DNA end at
the RSS side generated by RAG cleavage. This has a 5'P
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and 3'OH; CSR: class switch recombination; Class switch
sequences or regions: repetitive units of length 25 to 80
that compose the class switch recombination regions in
mammalian B cells; ALL: acute lymphoblastic leukemia
or lymphoma. The distinction of the leukemia or
lymphoma for ALL is largely arbitrary. If the patient
presents with extensive bone marrow and peripheral
blood ALL cells, then the designation leukemia is
preferred. If the patient presents with a mass lesion
and <25% ALL cells in the bone marrow, the term
lymphoma is preferred.
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